Related Experiment Videos

Complement C4-derived monocyte-directed chemotaxis-inhibitory factor. A molecular mechanism to cause

S Matsubara1, T Yamamoto, T Tsuruta

  • 1Department of Orthopaedic Surgery, Kumamoto University Medical School, Japan.

Insights

Rheumatoid arthritis synovial fluid suppresses monocyte infiltration via a complement C4-derived factor. This factor may explain why polymorphonuclear leukocytes dominate, driving chronic inflammation in joints.

Area of Science:

  • Immunology
  • Rheumatology
  • Molecular Biology

Background:

  • Rheumatoid arthritis (RA) is characterized by chronic joint inflammation.
  • Monocyte infiltration into synovial cavities is typically crucial in inflammatory processes.
  • The mechanism behind reduced monocyte infiltration in RA despite inflammation is unclear.

Purpose of the Study:

  • To investigate the mechanism limiting monocyte infiltration in rheumatoid arthritis synovial fluid.
  • To identify factors within synovial fluid that modulate leukocyte chemotaxis.

Main Methods:

  • Analysis of synovial fluid from 15 RA patients for leukocyte chemotactic activity.
  • Identification of inhibitory factors affecting monocyte chemotaxis using molecular weight and antigenicity assays.
  • Generation of inhibitors in normal plasma via complement system activation.

Main Results:

  • Synovial fluid showed strong chemotaxis for polymorphonuclear leukocytes but suppressed monocyte chemotaxis.
  • Two inhibitors were identified: alpha 1 protease inhibitor and an 8 kd factor sharing antigenicity with complement C4.
  • The C4-derived factor specifically inhibited monocyte chemotaxis, potentially by blocking signal transduction.
  • Removal of the C4-derived factor restored monocyte chemotactic ability.

Conclusions:

  • A C4-derived factor in RA synovial fluid significantly inhibits monocyte chemotaxis.
  • This inhibitor may be responsible for the predominant infiltration of polymorphonuclear leukocytes in RA joints.
  • Understanding this mechanism could offer new therapeutic targets for rheumatoid arthritis.

Related Concept Videos